Skip to main content
Fachgebiete
Automobil + Motoren Bauwesen + Immobilien Business IT + Informatik Elektrotechnik + Elektronik Energie + Nachhaltigkeit Finance + Banking Management + Führung Marketing + Vertrieb Maschinenbau + Werkstoffe Versicherung + Risiko
DE
EN
Bücher
Zeitschriften
Themenseiten
Organisationspsychologie Projektmanagement Marketing Smart Manufacturing
Weitere Formate
Podcasts Webinare Technik Webinare Wirtschaft Kongresse Veranstaltungskalender Awards
Jetzt Einzelzugang starten
Zugang für Unternehmen
Referenzkunden
SLX-Digitalkonferenz: Zukunftswerkstatt 2024

Mehr Umsatz mit Top-Kontakten

Am 7. Mai erfahren Sie, wie Vertriebsteams Leadgenerierung, Leadnurturing und Leadstrategien effizient steuern können.
Erweiterte Suche
Anmelden
nach oben
Erschienen in:
Optimal Biomarker-Guided Design for Targeted Therapy with Imperfectly Measured Biomarkers Kapitel lesen Erstes Kapitel lesen

2016 | OriginalPaper | Buchkapitel

A Statistical Model for Risk-Based Monitoring of Clinical Trials

verfasst von : Gregory J. Hather

Erschienen in: Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Analytics

Verlag: Springer International Publishing

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

Risk-based monitoring allows monitors of clinical trial sites to focus their visits on sites with the greatest potential for risk reduction. Here we present a statistical model that recommends sites for the monitor to visit. The model makes use of a pre-visit assessment supplied by the monitor, as well as other measurable factors, to predict the monitor’s post-visit assessment of the risk reduction resulting from the visit. The monitor is then directed to visit the sites with the highest predicted risk reduction. We demonstrate the properties of this model using a simulation. Our simulation compares two strategies for directing monitors, one of which relies on the model, while the other strategy relies only on the monitor’s pre-visit assessments. Our simulation demonstrates that the model-based strategy can direct the monitors to sites with greater potential for risk reduction. Finally, we discuss alternative models as well as potential pitfalls of risk-based monitoring.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 390 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Maschinenbau + Werkstoffe




 

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 340 Zeitschriften

aus folgenden Fachgebieten:

  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Versicherung + Risiko




Jetzt Wissensvorsprung sichern!

Jetzt informieren
Vorheriges Kapitel Some Misconceptions on the Use of Composite Endpoints
Nächstes Kapitel Blinded Safety Signal Monitoring for the FDA IND Reporting Final Rule
Literatur
Williams, G.W., 2006. The other side of clinical trial monitoring; assuring data quality and procedural adherence. Clinical Trials, 3(6), pp.530-537.
Morrison, B.W., Cochran, C.J., White, J.G., Harley, J., Kleppinger, C.F., Liu, A., Mitchel, J.T., Nickerson, D.F., Zacharias, C.R., Kramer, J.M. and Neaton, J.D., 2011. Monitoring the quality of conduct of clinical trials: a survey of current practices. Clinical Trials, 8(3), pp.342-349.
Bhatt, A., 2011. Quality of clinical trials: A moving target. Perspectives in clinical research, 2(4), p.124.
Oversight of Clinical Investigations: A Risk-Based Approach to Monitoring. U.S. Department of HHS, FDA, August 2013 OMB Control No. 0910–0733.
Hullsiek, K.H., Kagan, J.M., Engen, N., Grarup, J., Hudson, F., Denning, E.T., Carey, C., Courtney-Rodgers, D., Finley, E.B., Jansson, P.O. and Pearson, M.T., 2015. Investigating the Efficacy of Clinical Trial Monitoring Strategies Design and Implementation of the Cluster Randomized START Monitoring Substudy. Therapeutic innovation & regulatory science, 49(2), pp.225-233.
Franco, P., Hronec, M. and Karacsony, A., 2013. Risk-based monitoring: Reduce clinical trial costs while protecting safety and quality. PricewaterhouseCoopers.
Burgess, M. and ICONIK, I., 2013. Less is more: risk-based monitoring of site performance. ICON Insight, 13.
Reflection paper on risk based quality management in clinical trials. European Medicines Agency. 18 November 2013 EMA/269011/2013.
Timmermans, C., Doffagne, E., Venet, D., Desmet, L., Legrand, C., Burzykowski, T. and Buyse, M., 2016. Statistical monitoring of data quality and consistency in the Stomach Cancer Adjuvant Multi-institutional Trial Group Trial. Gastric Cancer, 19(1), pp.24-30.
Desmet, L., Venet, D., Doffagne, E., Timmermans, C., Burzykowski, T., Legrand, C. and Buyse, M., 2014. Linear mixed‐effects models for central statistical monitoring of multicenter clinical trials. Statistics in medicine, 33(30), pp.5265-5279.
Venet, D., Doffagne, E., Burzykowski, T., Beckers, F., Tellier, Y., Genevois-Marlin, E., Becker, U., Bee, V., Wilson, V., Legrand, C. and Buyse, M., 2012. A statistical approach to central monitoring of data quality in clinical trials. Clinical Trials, 9(6), pp.705-713.
Timmermans, C., Venet, D. and Burzykowski, T., 2015. Data-driven risk identification in phase III clinical trials using central statistical monitoring. International journal of clinical oncology, pp.1-8.
Zink, R.C., 2014. Risk-based monitoring and fraud detection in clinical trials using JMP and SAS. SAS Institute.
Taylor, R.N., McEntegart, D.J. and Stillman, E.C., 2002. Statistical techniques to detect fraud and other data irregularities in clinical questionnaire data. Drug information journal, 36(1), pp.115-125.
Buyse, M., George, S.L., Evans, S., Geller, N.L., Ranstam, J., Scherrer, B., Lesaffre, E., Murray, G., Edler, L., Hutton, J. and Colton, T., 1999. The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials. Statistics in medicine, 18(24), pp.3435-3451.
Al-Marzouki, S., Evans, S., Marshall, T. and Roberts, I., 2005. Are these data real? Statistical methods for the detection of data fabrication in clinical trials. Bmj, 331(7511), pp.267-270.
George, S.L. and Buyse, M., 2015. Data fraud in clinical trials. Clinical investigation, 5(2), pp.161-173.
Tantsyura, V., Dunn, I.M., Fendt, K., Kim, Y.J., Waters, J. and Mitchel, J., 2015. Risk-Based Monitoring A Closer Statistical Look at Source Document Verification, Queries, Study Size Effects, and Data Quality. Therapeutic Innovation & Regulatory Science, 49(6), pp.903-910.
Nielsen, E., Hyder, D. and Deng, C., 2013. A data-driven approach to risk-based source data verification. Therapeutic Innovation & Regulatory Science, p.2168479013496245.
van den Bor, R.M., Oosterman, B.J., Oostendorp, M.B., Grobbee, D.E. and Roes, K.C., 2016. Efficient Source Data Verification Using Statistical Acceptance Sampling A Simulation Study. Therapeutic Innovation & Regulatory Science, 50(1), pp.82-90.
DeMars, C. (2010). Item Response Theory. Oxford, UK: Oxford University Press.
Crawley, M. J. (2012) Mixed-Effects Models, in The R Book, Second Edition, John Wiley & Sons, Ltd, Chichester, UK.
Rabiner, L.R. and Juang, B.H., 1986. An introduction to hidden Markov models. ASSP Magazine, IEEE, 3(1), pp.4-16.
Rubin, D.B., 1976. Inference and missing data Biometrika 63 (3): 581–592. Find this article online.
Power, D.J., Sharda, R. and Burstein, F., 2015. Decision support systems. John Wiley & Sons, Ltd.
Khan, F.I. and Haddara, M.M., 2003. Risk-based maintenance (RBM): a quantitative approach for maintenance/inspection scheduling and planning. Journal of Loss Prevention in the Process Industries, 16(6), pp.561-573.
Thomas, L.C., 2000. A survey of credit and behavioural scoring: forecasting financial risk of lending to consumers. International journal of forecasting, 16(2), pp.149-172.
Metadaten
Titel
A Statistical Model for Risk-Based Monitoring of Clinical Trials
verfasst von
Gregory J. Hather
Copyright-Jahr
2016
Buch
Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Analytics

Print ISBN: 978-3-319-42567-2

Electronic ISBN: 978-3-319-42568-9

Copyright-Jahr: 2016

DOI
https://doi.org/10.1007/978-3-319-42568-9_16